Boehringer Ingelheim GmbH - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 174 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Boehringer Ingelheim GmbH - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Boehringer Ingelheim GmbH - Product Pipeline Review - 2014', provides an overview of the Boehringer Ingelheim GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Boehringer Ingelheim GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Boehringer Ingelheim GmbH including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Boehringer Ingelheim GmbH's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Boehringer Ingelheim GmbH's pipeline products

Reasons to buy

- Evaluate Boehringer Ingelheim GmbH's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Boehringer Ingelheim GmbH in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Boehringer Ingelheim GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Boehringer Ingelheim GmbH and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Boehringer Ingelheim GmbH
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Boehringer Ingelheim GmbH and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Boehringer Ingelheim GmbH Snapshot 6
Boehringer Ingelheim GmbH Overview 6
Key Information 6
Key Facts 6
Boehringer Ingelheim GmbH - Research and Development Overview 7
Key Therapeutic Areas 7
Boehringer Ingelheim GmbH - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Pipeline Products - Partnered Products 17
Pipeline Products - Out-Licensed Products 19
Boehringer Ingelheim GmbH - Pipeline Products Glance 21
Boehringer Ingelheim GmbH - Late Stage Pipeline Products 21
Boehringer Ingelheim GmbH - Clinical Stage Pipeline Products 23
Boehringer Ingelheim GmbH - Early Stage Pipeline Products 26
Boehringer Ingelheim GmbH - Drug Profiles 28
(empagliflozin + linagliptin) 28
(empagliflozin + metformin) 29
(olodaterol + tiotropium bromide) 30
empagliflozin 32
nintedanib 34
olodaterol 38
tiotropium bromide 40
(linagliptin + pioglitazone hydrochloride) 42
adalimumab biosimilar 44
afatinib 45
Idarucizumab 48
rituximab biosimilar 49
volasertib 50
BI-144807 52
BI-187004 53
BI-409306 54
BI-655066 55
BI-671800 56
VTP-34072 57
BI-811283 59
BI-836845 60
ambroxol 62
bevacizumab biosimilar 63
BI-1005273 64
BI-1015550 65
BI-1021958 66
BI-1026706 67
BI-1060469 68
BI-113608 69
BI-1181181 70
BI-163538XX 71
BI-416970 72
BI-425809 73
BI-655064 74
BI-836826 75
BI-836858 76
BI-847325 77
BI-853520 78
BI-860585 80
CV-9202 81
Small Molecule for Cancer 82
VTP-37948 83
BCA-909 84
BIBN-4096BS 86
CNX-012 88
CNX-012570 89
EVT-070 90
FX-125L 91
FX-141L 93
FX-87L 94
Monoclonal Antibodies for Cancer and Pulmonary Diseases 95
OX-MPI 96
sabiporide 97
Small Molecule 2 for Cancer 99
Small Molecule 3 for Cancer 100
Small Molecule for Pain 101
Small Molecule for Rhinovirus Infection 102
Small Molecule to Agonize Glucocorticoid Receptor for Inflammation 103
Small Molecule to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection 104
Small Molecules for Respiratory Disorders 105
Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy 106
Antibody Program for Cancer 107
Drug to Inhibit Reverse Transcriptase for HIV-1 108
Monoclonal Antibody for Undisclosed Indication 109
Small Molecule for HIV 110
Small Molecule for HIV-1 Infection 111
Small Molecule for Respiratory Diseases 112
Small Molecule to Agonize Glucocorticoid Receptor for Undisclosed Indication 113
Small Molecule to Inhibit Reverse Transcriptase for HIV-1 infection 114
Small Molecules for Undisclosed Indication 115
Small Molecules to Inhibit Kinases for Cancer 116
Small Molecules to Modulate PPIs for Cancer 117
Boehringer Ingelheim GmbH - Pipeline Analysis 118
Boehringer Ingelheim GmbH - Pipeline Products by Target 118
Boehringer Ingelheim GmbH - Pipeline Products by Route of Administration 122
Boehringer Ingelheim GmbH - Pipeline Products by Molecule Type 123
Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action 124
Boehringer Ingelheim GmbH - Recent Pipeline Updates 127
Boehringer Ingelheim GmbH - Dormant Projects 157
Boehringer Ingelheim GmbH - Discontinued Pipeline Products 159
Discontinued Pipeline Product Profiles 159
Boehringer Ingelheim GmbH - Company Statement 162
Boehringer Ingelheim GmbH - Locations And Subsidiaries 165
Head Office 165
Other Locations & Subsidiaries 165
Appendix 168
Methodology 168
Coverage 168
Secondary Research 168
Primary Research 168
Expert Panel Validation 168
Contact Us 169
Disclaimer 169

List of Tables
Boehringer Ingelheim GmbH, Key Information 11
Boehringer Ingelheim GmbH, Key Facts 11
Boehringer Ingelheim GmbH - Pipeline by Indication, 2014 14
Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2014 19
Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2014 20
Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2014 21
Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2014 22
Boehringer Ingelheim GmbH - Partnered Products/ Combination Treatment Modalities, 2014 23
Boehringer Ingelheim GmbH - Out-Licensed Products in Pipeline, 2014 24
Boehringer Ingelheim GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2014 25
Boehringer Ingelheim GmbH - Pre-Registration, 2014 26
Boehringer Ingelheim GmbH - Phase III, 2014 27
Boehringer Ingelheim GmbH - Phase II, 2014 28
Boehringer Ingelheim GmbH - Phase I, 2014 29
Boehringer Ingelheim GmbH - Preclinical, 2014 31
Boehringer Ingelheim GmbH - Discovery, 2014 32
Boehringer Ingelheim GmbH - Pipeline by Target, 2014 124
Boehringer Ingelheim GmbH - Pipeline by Route of Administration, 2014 127
Boehringer Ingelheim GmbH - Pipeline by Molecule Type, 2014 128
Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action, 2014 129
Boehringer Ingelheim GmbH - Recent Pipeline Updates, 2014 132
Boehringer Ingelheim GmbH - Dormant Developmental Projects,2014 162
Boehringer Ingelheim GmbH - Discontinued Pipeline Products, 2014 164
Boehringer Ingelheim GmbH, Subsidiaries 170